A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome

© 2020, The American College of Clinical Pharmacology..

Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19.

Media Type:

Electronic Article

Year of Publication:

2020

Contained In:

Journal of clinical pharmacology - Vol. 60, No. 9 (2020), p. 1131-1146

Language:

English

Contributors:

Khiali, Sajad
Khani, Elnaz
Entezari-Maleki, Taher

Links:

Volltext

Keywords:

ARDS
Acute lung injury
Antibodies, Monoclonal, Humanized
COVID-19
CRS
Cytokine Release Syndrome
Humans
I031V2H011
IL-6
Interleukin-6
Journal Article
Respiratory Distress Syndrome
Review
SARS-CoV-2
Tocilizumab

Notes:

Date Completed 14.12.2020

Date Revised 14.12.2020

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1002/jcph.1693

PMID:

32557541

PPN (Catalogue-ID):

NLM312264569